EC sets new deadline for Zentiva competition review
This article was originally published in Scrip
Executive Summary
The European Commissionhas moved the deadline for the completion of its competition review of Sanofi-Aventis's proposal to buy Zentivafrom January 21st to February 4th. At the end of last year, the EU regulators said that the deal notification was incomplete and asked them to re-notify (Scrip Online, November 12th, 2008). Sanofi-Aventis might have proposed concessions such as the sale of affiliated companies to reduce its potential dominance in one or more countries after the merger. The board of the Czech Republic's largest manufacturer of generic drugs accepted Sanofi-Aventis's proposal to pay €1.8 billion for all ofits shares on September 22nd.
You may also be interested in...
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Medvedev wants talks on trials mutual recognition with US and EU
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.